AION Labs, a venture studio centered on reshaping pharmaceutical research and development through breakthrough technologies, has named Dr. Ilana Mandel as Chief Scientific Officer and Dr. Shira Warszawski as Chief Technology Officer. The appointments arrive as the venture studio broadens its operational model to identify, develop, and scale a more diverse array of technologies tackling critical hurdles in the pharmaceutical R&D sector.
Originally established in 2021 with an emphasis on artificial intelligence in drug discovery, AION Labs is now extending its scope into quantum technologies, robotics, and laboratory automation alongside biology and AI. The studio was founded by major global pharmaceutical, technology, and investment participants, including AstraZeneca, Merck, Pfizer, Teva, Amazon Web Services (AWS), Amiti Ventures, and the Israel Biotech Fund, with backing from the Israel Innovation Authority. To date, the biotech venture studio has created 12 startups, finalized more than 22 Proof of Concept projects, and realized its first exit earlier in the year when Silicon Valley-based insitro acquired CombinAble.AI.
Dr. Ilana Mandel steps into her role with over 15 years of experience in drug discovery and development, having advanced therapeutic programs from early scientific stages to the clinic. Her prior roles include serving as Chief Scientific Officer at Biond Biologics, where she guided the creation of first-in-human candidates and managed a licensing agreement with Sanofi. Before that, she directed research at cCAM Biotherapeutics prior to its acquisition by MSD. At AION Labs, Mandel will head scientific strategy and help pinpoint biological and therapeutic opportunities for upcoming companies and platforms.
Dr. Shira Warszawski brings over 15 years of experience across computational protein design, biotherapeutic R&D, global pharmaceutical organizations, and biotechnology startups. Her background includes leading therapeutic protein design at Merck KGaA, CRISPR nuclease engineering teams at Emendo Bio, and protein design software development at Scala Biodesign. In her position as Chief Technology Officer, Warszawski will direct AION Labs' technology strategy, evaluating emerging capabilities and helping convert them into platforms and enterprises addressing high-value R&D challenges.
The leadership shift also coincides with a transition for Dr. Yair Benita, Co-Founder and Chief Technology Officer, who has been instrumental in building AION Labs since its inception. Benita will step away from his current post to head Phindex, an enterprise conceived and developed within AION Labs that is creating an AI-powered platform to assist biotech companies in steering drug development from initial molecules toward IND submission.
Additionally, AION Labs has appointed veteran biotech executive Ram Waisbourd as Venture Partner to support portfolio company growth, strategic development, and venture creation activities. Waisbourd brings over 25 years of biotech leadership experience, including a decade at Teva Pharmaceuticals and co-founding 89bio, where he served as Chief Operating Officer and Chief Business Officer, and later as a business development advisor during its acquisition by Roche in 2025.
